Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Targeting MTAP increases PARP inhibitor susceptibility in triple-negative breast cancer through a feed-forward loop
Tu, Xinyi , Zhang, Yong , Hou, Jing , Zhu, Shouhai , Wu, Zheming , Hao, Yalan , Zhang, Lingxin , Weinshilboum, Richard M. , Tao, Kaixiong , Wang, Liewei , Zhu, Shouhai , Zeng, Xiangyu , Zhao, Fei , Yang, Wen‐Bin , Jiang, Qi , Weinshilboum, Richard M. , Lou, Zhenkun

Mayo Clinic

Journal of Clinical Investigation | June 30, 2025 | Volume: 135 | Issue: 13 | Pages: No page available

10.1172/jci188120 | PMID 40590219 Get It

Triple-negative breast cancer (TNBC) represents the most malignant subtype of breast cancer. The clinical application of PARP inhibitors (PARPi) is limited by the low frequency of BRCA1/2 mutations in TNBC. Here, we identified that MTAP deletion sensitized genotoxic agents in our clinical cohort of metastatic TNBC. Further study demonstrated that MTAP deficiency or inhibition rendered TNBC susceptibility to chemotherapeutic agents, particularly PARPi. Mechanistically, targeting MTAP that synergized with PARPi by disrupting the METTL16-MAT2A axis involved in methionine metabolism and depleting in vivo s-adenosylmethionine (SAM) levels. Exhausted SAM in turn impaired PARPi-induced DNA damage repair through attenuation of MRE11 recruitment and end resection by diminishing MRE11 methylation. Notably, brain metastatic TNBC markedly benefited from a lower dose of PARPi and MTAP deficiency/inhibition synergy due to the inherently limited methionine environment in the brain. Collectively, our findings revealed a feed-forward loop between methionine metabolism and DNA repair through SAM, highlighting a therapeutic strategy of PARPi combined with MTAP deficiency/inhibition for TNBC.
Comparison of Frontline Therapies in Older Adults Age ≥ 80 Years With Chronic Lymphocytic Leukemia (CLL): A Mayo Clinic and Danish Nation‐Wide Study
Tsang, Mazie , Hampel, Paul J. , Rabe, Kari G. , Ding, Wei , Leis, José F., Kenderian, Saad S. , Wang, Yucai , Muchtar, Eli , Koehler, Amber B. , Dyke, Daniel L. Van , Hanson, Curtis A. , Hjalgrim, Henrik , Ding, Wei , Kenderian, Saad Sirop , Wang, Yucai , Muchtar, E , Van Dyke, Daniel L, Shi, Min , Parikh, Sameer A , Chaffee, Kari G. , Tsang, Mazie , Brieghel, Christian , Hilal, Talal , Slager, Susan L. , Kay, Neil E. , Niemann, Carsten Utoft , Parikh, Sameer A. , Rotbain, Emelie Curovic

Mayo Clinic

American Journal of Hematology | June 29, 2025 | Volume: 100 | Issue: 9 | Pages: 1678-1681

10.1002/ajh.27747 | PMID 40530575 Get It

Impact of CKD/Kidney Failure on Angiodysplasia-Related Gastrointestinal Bleeding
He, Mingyue , Shah, Ankur , Wang, Yichen , Gillespie, Avrum , Shah, Ankur D , Wang, Yichen

Mayo Clinic

Kidney360 | June 27, 2025 | Volume: 6 | Issue: 10 | Pages: 1689-1701

10.34067/kid.0000000901 | PMID 40577068 Get It

Key Points First US national study showing angiodysplasia-related gastrointestinal bleeding incidence and readmissions rises progressively with worsening CKD stage. Patients with kidney failure were less likely to receive endoscopy, which was linked to higher mortality, revealing a potential care gap. Recurrent angiodysplasia-related gastrointestinal bleeding was the leading cause of 30-day readmission; lack of endoscopy was an independent predictor of readmission. Background Angiodysplasia-related gastrointestinal bleeding (AGIB) is an increasingly recognized cause of hospitalization, particularly among patients with CKD. Although AGIB has been linked to kidney failure (KF), its burden across CKD stages remains unclear. This study aimed to evaluate AGIB incidence, outcomes, and readmissions across CKD stages using the largest inpatient and readmission databases in the United States. Methods We conducted a retrospective cohort study using the 2022 National Inpatient Sample and Nationwide Readmissions Database. Adult patients hospitalized with AGIB were identified and stratified into five groups: non-CKD, early CKD (stage 3), advanced CKD (stages 4–5 not on dialysis), KF (ESKD requiring chronic dialysis), and others. The primary outcome was AGIB hospitalization incidence. Secondary outcomes included in-hospital mortality, disease severity, treatment interventions, health care utilization, and 30-day readmission. Multivariable regression models were used to identify independent risk. Results In 2022, 46,670 adults were hospitalized with AGIB (0.17% of all admissions). CKD/KF was an independent risk factor for AGIB hospitalization, with risk increasing progressively with worsening kidney function (adjusted odds ratio [aOR]: 1.42 [1.34 to 1.50; early CKD], 1.89 [1.72 to 2.07; advanced CKD], 2.51 [2.32 to 2.72; KF]; all P < 0.001). The overall in-hospital mortality rate was 1.04%, higher among patients with CKD. KF was independently associated with higher mortality (aOR, 1.87 [1.06 to 3.27]), lower rates of endoscopic evaluation (aOR, 0.53 [0.43 to 0.65]), and longer hospital stays. Endoscopy was associated with lower mortality (aOR, 0.54 [0.32 to 0.92]). The 30-day all-cause readmission rate was 22.3%, with recurrent AGIB as the leading cause. Readmission risk increased progressively with CKD stage. Conclusions CKD progression is strongly associated with increased risk of AGIB hospitalization and readmission. KF and lack of endoscopic evaluation were independent mortality risk factors. These findings highlight the need for proactive management strategies in this high-risk population.
Nuclear Medicine Lymphoscintigraphy: Applications and Technical Overview
Basavalingu, Deepashri , Elojeimy, Saeed , Mercer, Megan K. , Itani, Malak , Revels, Jonathan , Blacklock, Lisa C. , Wang, Sherry S. , Kolokythas, Orpheus , Behnia, Fatemeh , Revels, Jonathan W , Zuckier, Lionel S, Wang, Sherry S , Kolokythas, Orpheus , Behnia, Fatemeh , Itani, Malak , Basavalingu, Deepashri , Zuckier, Lionel S.

Mayo Clinic

RadioGraphics | June 26, 2025 | Volume: 45 | Issue: 7 | Pages: No page available

10.1148/rg.240207 | PMID 40569836 Get It

Lymphoscintigraphy, which is commonly used for sentinel lymph node mapping, can help diagnose lymphedema, lymphatic leakage, and lymphatic malformations and provides valuable information for surgical planning and treatment.
Karyotypic clonal fraction predicts adverse outcome in TP53 -mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study
Pandiri, M, Stengel, Anna , Shao, Haipeng , Velmurugan, S. , Jacob, Anisha, Symes, Emily , Kaur, Amandeep , Rojek, Alexandra E. , Sojitra, Payal , Wiredja, Danica , Chang, Hong , Patil, Esha, Patel, Jay , Patel, Ami B. , Pan, Zenggang , Findley, Anthony, Badar, Talha , Tariq, Hamza , Sallman, David A. , Bell, Robert , Perry, Anamarija M. , Fitzpatrick, Carrie , Pandiri, Madhavi , Zhou, Qianghua , Venkataraman, Girish , Badar, Talha , Rojek, Alexandra E , Zhang, Jingjing , Wang, Peng , Shao, Haipeng, Jacob, Anisha, Menon, Madhu P , Ghosh, Sharmila , Wool, Geoffrey D. , Arber, Daniel A. , Findley, Anthony, Haferlach, Claudia

Mayo Clinic

Journal of Clinical Pathology | June 26, 2025 | Volume: 78 | Issue: 9 | Pages: 629-635

10.1136/jcp-2024-209954 | PMID 40571403 Get It

We investigated the prognostic impact of blast counts, TP53 allelic state determinants (number of hits, del(17p), variant allele frequency, complex karyotype),and a novel karyotypic clonal cell fraction (≤50% clonal cells vs >50% clonal cells (termed ‘CK50’)) in 495 individuals with TP53- mutated ( TP53 MUT ) myeloid neoplasms. Outcome examined was 24-month survival (OS24). The cohort (median age 71) included 29% (144/495) myelodysplastic syndromes (MDS)/MDS-acute myeloid leukaemia (AML) (1%–19% blasts) and 71% (351/495) AML (≥20% blasts), with 18% (81/460) having low CK50. Overall, 83% received front-line hypomethylating agents. Higher blast counts (<20% vs ≥20%) were marginally associated with CK50 (p=0.08). In the OS24 analysis, blast count showed a marginal association with OS24 (HR 1.3 (95% CI 1.0 to 1.6); p=0.07), while CK50 predicted significantly inferior outcomes (HR=1.7 (95% CI 1.2 to 2.3); p=0.002). In a multivariable model including all TP53 allelic state determinants, only CK50 and complex karyotype remained relevant for predicting adverse outcomes.
A curriculum for epilepsy surgery: A report from the Surgical Commission's Epilepsy Surgery Educational Task Force and the Educational Council of the ILAE
Dorfer, Christian , Enslin, Nico , Olivera, Tatiana von Hertwig Fernandes de, Wiebe, Samuel , Alotaibi, Faisal , Ali, Rushna , Englot, Dario J. , Cross, J. Helen , Ali, Rushna P, Dorfer, Christian , Englot, Dario J , Cross, Helen J , Nico Enslin, Johannes M , Muh, Carrie R. , Wang, Xiongfei , Wiebe, Samuel , McKhann, Guy M. , Damisah, Eyiyemisi C. , Singh, Gagandeep , Blümcke, Ingmar , Rydenhag, Bertil , Alonso‐Vanegas, Mario , Cukiert, Arthur

Mayo Clinic

Epileptic Disorders | June 26, 2025 | Volume: 27 | Issue: 5 | Pages: 718-728

10.1002/epd2.70054 | PMID 40569634 Get It

Abstract Objective There is a need to develop a comprehensive, formalized, and globally applicable epilepsy surgery curriculum in order to help standardize the quality of epilepsy surgery practice in the world. Methods The Epilepsy Surgery Educational Task Force of the ILAE developed a competency‐based epilepsy surgery educational curriculum comprised of four domains: Diagnosis, Counseling, Pre‐surgical Work‐up, and Surgical Techniques. To evaluate this educational curriculum, a survey questionnaire consisting of 11 items was sent out for feedback to ILAE and IESS members. The survey questionnaire asked respondents to rate the degree of importance of each competency on a five‐point scale that ranged from “extremely important” to “not at all important” and provided space for free text comments. All competencies that were rated as “slightly important” or “somewhat important” by more than 10% of responders, as well as all free text feedback comments, were fully reviewed, and the final curriculum was adjusted accordingly. Results One hundred and twenty‐two responses ( n = 122) were submitted by the ILAE and IESS communities. Seventy‐one percent (71.9%) of the responses came from neurosurgeons of varied experience and training levels. Ninety‐four percent (94.4%) of responders stated that they “support a curriculum to determine the competency of neurosurgeons participating in the care of people with epilepsy in my country,” and 94.3% confirmed that they “would be interested in taking or would recommend an ILAE course based on these competencies, that would provide an ILAE certificate of completion.” Relevant changes within the curriculum were made based on feedback. Significance The newly developed ILAE comprehensive epilepsy surgery educational curriculum has a high level of support from neurosurgeons and neurologists around the world and shows potential for broad acceptance and implementation.
BraTS-PEDs: Results of the Multi-Consortium International Pediatric Brain Tumor Segmentation Challenge 2023
Kazerooni, Anahita Fathi , Khalili, Nastaran, Liu, Xinyang , Jiang, Zhifan , Pavaine, Julija , Jones, Blaise V. , Sheth, Nakul , McAllister, Aaron S. , Tu, Wenxin , Rodriguez, Andres Fernandez, Shaikh, Ibraheem S , Sanchez-Montano, Mariana , Lai, Hollie Anne , Adewole, Maruf , Albrecht, Jake, Anazodo, Udunna, Anwar, Syed Muhammed, Aristizábal, Alejandro , Baid, Ujjwal , Bergquist, Timothy , Conte, Gian-Marco, Eddy, James A. , Ezhov, Ivan , Gandhi, Deep , Gottipati, Anurag , Haldar, Shuvanjan, Janas, Anastasia , Elaine, Elaine, Karargyris, Alexandros , Kassem, Hasan, Khalili, Neda , Maleki, Nazanin , Meier, Zeke, Saluja, Rachit , Sheller, Micah , Shinohara, Russell Takeshi, Viswanathan, Karthik , Wang, Chunhao , Storm, Phillip B. , Packer, Roger, Hummel, Trent R. , Hoffman, Lindsey M. , Nabavizadeh, Ali , Ware, Jeffrey B., Rood, Brian , Resnick, Adam J., Linguraru, Marius George , Khalili, Nastaran, Haldar, Debanjan , Zapaishchykova, Anna , Shah, Lubdha M. , Prabhu, Sanjay P. , Nandolia, Khanak , Anderson, Hannah, Bagheri, Sina , Borja, Austin J. , Calabrese, Evan , Chung, Verena , Familiar, Ariana , Farahani, Keyvan , Iglesias, Juan Eugenio , Kofler, Florian , LaBella, Dominic , Leemput, Koen Van , Li, Hongwei , Meier, Zeke, Menze, Bjoern H. , Moawad, Ahmed W. , Pati, Sarthak , Piraud, Marie , Poussaint, Tina Young , Reitman, Zachary J. , Rudie, Jeffrey D. , Shinohara, Russell Taki , Wiestler, Benedikt , Wiggins, Walter F. , Davatzikos, Christos , Bornhorst, Miriam , Blank, Peter M K de , Aboian, Mariam , Kann, Benjamin H. , Bakas, Spyridon , Vossough, Arastoo

Mayo Clinic

Machine Learning for Biomedical Imaging | June 26, 2025 | Volume: 3 | Issue: June 2025 | Pages: 72-87

10.59275/j.melba.2025-f6fg Get It

Pediatric central nervous system tumors are the leading cause of cancer-related deaths in children. The five-year survival rate for high-grade glioma in children is less than 20%. The development of new treatments is dependent upon multi-institutional collaborative clinical trials requiring reproducible and accurate centralized response assessment. We present the results of the BraTS-PEDs 2023 challenge, the first Brain Tumor Segmentation (BraTS) challenge focused on pediatric brain tumors. This challenge utilized data acquired from multiple international consortia dedicated to pediatric neuro-oncology and clinical trials. BraTS-PEDs 2023 aimed to evaluate volumetric segmentation algorithms for pediatric brain gliomas from magnetic resonance imaging using standardized quantitative performance evaluation metrics employed across the BraTS 2023 challenges. The top-performing AI approaches for pediatric tumor analysis included ensembles of nnU-Net and Swin UNETR, Auto3DSeg, or nnU-Net with a self-supervised framework. The BraTS-PEDs 2023 challenge fostered collaboration between clinicians (neuro-oncologists, neuroradiologists) and AI/imaging scientists, promoting faster data sharing and the development of automated volumetric analysis techniques. These advancements could significantly benefit clinical trials and improve the care of children with brain tumors.
The Brain Tumor Segmentation (BraTS-METS) Challenge 2023: Brain Metastasis Segmentation on Pre-treatment MRI
Janas, Anastasia , Baid, Ujjwal , Ramakrishnan, Divya , Saluja, Rachit , Ashraf, Nader, Maleki, Nazanin , Yordanov, Nikolay , Fehringer, Pascal, Gkampenis, Athanasios , Amiruddin, Raisa, Adewole, Maruf , Albrecht, Jake, Anazodo, Udunna, Anwar, Syed Muhammad, Bergquist, Timothy , Chiang, Veronica , Eddy, J. Mark , Ezhov, Ivan , Khalili, Nastaran, Jiang, Zhifan , Johanson, Elaine, Kazerooni, Anahita Fathi , Krantchev, Kiril, Linguraru, Marius George , Liu, Xinyang , Meier, Zeke, Moy, Harrison, Osenberg, Klara , Reitman, Zachary, Shinohara, Russell Takeshi, Wang, Chunhao , Shafique, Umber, Willms, Klara, Avesta, Arman , Bousabarah, Khaled , Chakrabarty, Satrajit , Gennaro, Nicolò , Holler, Wolfgang, Lost, Jan , Marcus, Daniel S. , Maresca, R, Merkaj, Sarah, Pedersen, Gabriel Cassinelli, Reppert, Marc von , Teytelboym, Oleg M., Tillmans, Niklas, Westerhoff, Malte , Youssef, Ayda , Pflüger, Irada, Perez-Carillo, Gloria J. Guzman, Memon, Fatima, Krycia, Mark, Patro, Satya Narayana , Petrović, Bojan , Schrickel, E. Brooke, Besada, Cristina , Chu, Sammy, Dusoi, Alexandru, Farage, Luciano , Fong, Amy, Gray, R. Ian, Krumpelman, Chase, Lincoln, Christie M. , Maros, Máté E. , Morón, Fanny , Nimchinsky, Esther A. , Patel, Uresh, Rohatgi, Saurabh , Sayah, Anousheh , Schwartz, Eric D. , Shiroishi, Mark S. , Valerie, Jewels, White, Matthew L. , Zohrabian, Vahe M. , Brüßeler, Melanie, Ghonim, Mohamed, Okar, Abdullah , Pasquini, L. , Soumala, Theodora, Taherzadeh, Mahsa , Vollmuth, Philipp, Foltyn, Martha , Abayazeed, Aly, Dellepiane, Francesco , Verdier, Maria Correia de , Al-Rubaiey, Sanaria, Ashraf, Kholod, Asla, Moamen M., Badawy, Mohamed , Lomer, Nima Broomand , Bukatz, Jan, Chen, Jim, Cimflová, Petra , Corr, Felix, Crawley, Alexis, Deptula, Lisa, Elakhdar, Tasneem, Shawali, Islam H., Frick, Alexandra, Haider, Muhammad Ammar , Hierro, Fátima , Jacobs, Sarah Maria, Hsieh, Kuang-chun Jim, Kersting, Katharina , Kida, Laura, Kollia, Sofia , Koukoulithras, Ioannis, Li, Xiao , Abouelatta, Ahmed, Mansour, Aya, Maria-Zamfirescu, Ruxandra-Catrinel, Marsiglia, Marcela , Mateo-Camacho, Yohana Sarahi , McArthur, Mark J., McDonnell, Olivia, McHugh, M, Moassefi, Mana , Morsi, Samah Mostafa, Munteanu, Alexander , Naqvi, Syed Raza, Nikanpour, Yalda , Alnoury, Mostafa , Nouh, Abdullah Mohamed Aly, Pappafava, Francesca, Patel, Markand D., Petrucci, S. , Rawie, Eric, Raymond, Scott B. , Roohani, Borna, Sabouhi, Sadeq, Sánchez‐García, Laura , Shaked, Zoe , Altes, Talissa A. , Isufi, Edvin , Dhemesh, Yaseen , Gass, Jaime, Thacker, Jonathan, Tarabishy, Abdul , Turner, Benjamin , Worede, Fikadu , Yousry, Sara, Lerebo, Wondwossen , Aristizábal, Alejandro , Karargyris, Alexandros , Kassem, Hasan , Sheller, Micah , Link, Katherine E. , Moawad, Ahmed W. , Ashraf, Nader, Jekel, Leon , Manteghinejad, Amirreza , Aneja, Sanjay , Anwar, Syed Muhammad, Chung, Verena , Conte, Gian Marco , Dako, Farouk , Eddy, James, Khalili, Nastaran, Farahani, Keyvan , Iglesias, Juan Eugenio , Kofler, Florian , LaBella, Dominic , Leemput, Koen Van , Li, Hongwei , Meier, Zeke, Menze, Bjoern H. , Piraud, Marie , Shinohara, Russell Taki , Wiestler, Benedikt , Wiggins, Walter F. , Kaur, Manpreet , LaMontagne, Pamela , Lin, MingDe , Maresca, Ryan, Petersen, Gabriel Cassinelli , Sotiras, Aristeidis , Godfrey, Devon , Floyd, Scott , Rauschecker, Andreas M. , Villanueva-Meyer, Javier E. , Cho, Jaeyoung , Bendszus, Martin , Brugnara, Gianluca , Cramer, Justin , Johnson, Derek R. , Kam, Anthony , Kwan, Benjamin Y. M. , Lai, Lillian M. , Lall, Neil , So, Tiffany Y. , Thompson, Gerard , Wu, Lei , Bansal, Anu , Barkhof, Frederik , Druzgal, T. Jason , Feltrin, Fabrício Stewan , Fung, Steve H. , Ikuta, Ichiro , Iv, Michael , Postma, Alida A. , Mahajan, Amit Kumar , Joyner, David , Létourneau‐Guillon, Laurent , Miller, Elka , Özsarlak, Ö. , Saha, Atin , Shih, Robert , Small, Juan E. , Tanwar, Manoj , Weinberg, Brent D. , Young, Robert J. , Azizova, Aynur , Ghonim, Mohanad , Ghonim, Mohamed, Sharifi, Yasaman , Singh, Gagandeep, Sollmann, Nico , Vollmuth, Philipp, Foltyn‐Dumitru, Martha , Malhotra, Ajay , Lohmann, Philipp , Pérez‐García, Víctor M. , Elhalawani, Hesham M. , Duarte Armindo, Rui , Asla, Moamen M., Bisschop, Jeroen , Faghani, Shahriar , Gulati, Vaibhav , Dahl, Rasmus Holmboe , McArthur, Mark, McHugh, Maire, Moassefi, Mana , Nandolia, Khanak , Petrucci, Samantha, Sanchez-Garcia, Laura M., Suthar, Pokhraj Prakashchandra , Vacca, Sebastiano , Vilanilam, George K. , Warren, Daniel, Weiss, David, Pati, Sarthak , Calabrese, Evan , Tahon, Nourel Hoda , Nada, Ayman , Velichko, Yury , Bakas, Spyridon , Rudie, Jeffrey D. , Aboian, Mariam

Mayo Clinic

Machine Learning for Biomedical Imaging | June 26, 2025 | Volume: 3 | Issue: December 2025 | Pages: 204-247

10.59275/j.melba.2025-9bd3 Get It

The translation of AI-generated brain metastases (BM) segmentation into clinical practice relies heavily on diverse, high-quality annotated medical imaging datasets. The BraTS-METS 2023 challenge has gained momentum for testing and benchmarking algorithms using rigorously annotated internationally compiled real-world datasets. This study presents the results of the segmentation challenge and characterizes the challenging cases that impacted the performance of the winning algorithms. Untreated brain metastases on standard anatomic MRI sequences (T1, T2, FLAIR, T1PG) from eight contributed international datasets were annotated in stepwise method: published UNET algorithms, student, neuroradiologist, final approver neuroradiologist. Segmentations were ranked based on lesion-wise Dice and Hausdorff distance (HD95) scores. False positives (FP) and false negatives (FN) were rigorously penalized, receiving a score of 0 for Dice and a fixed penalty of 374 for HD95. The mean scores for the teams were calculated. Eight datasets comprising 1303 studies were annotated, with 402 studies (3076 lesions) released on Synapse as publicly available datasets to challenge competitors. Additionally, 31 studies (139 lesions) were held out for validation, and 59 studies (218 lesions) were used for testing. Segmentation accuracy was measured as rank across subjects, with the winning team achieving a LesionWise mean score of 7.9. The Dice score for the winning team was 0.65 ± 0.25. Common errors among the leading teams included false negatives for small lesions and misregistration of masks in space. The Dice scores and lesion detection rates of all algorithms diminished with decreasing tumor size, particularly for tumors smaller than 100 mm3. In conclusion, algorithms for BM segmentation require further refinement to balance high sensitivity in lesion detection with the minimization of false positives and negatives. The BraTS-METS 2023 challenge successfully curated well- annotated, diverse datasets and identified common errors, facilitating the translation of BM segmentation across varied environments and providing the tools for future development of personalized volumetric reports to patients undergoing BM treatment.
Extended Sural Nerve Harvest: A Technique to Gain Additional Graft Length
Millesi, Elena , Gates-Tanzer, Lauren, Felzen, Antonia , Wang, Huan, Gibreel, Waleed , Mardini, Samir

Mayo Clinic

Plastic & Reconstructive Surgery | June 25, 2025 | Volume: 157 | Issue: 1 | Pages: 99e-107e

10.1097/prs.0000000000012270 | PMID 40558058 Get It

Background: The sural nerve is widely used as a nerve graft for various types of peripheral nerve repair due to its ease of harvest and acceptable donor-site morbidity. Nevertheless, certain clinical scenarios, such as cable grafting or multiple cross-face nerve grafts, require grafts longer than the typical 35 cm. This study aims to investigate the anatomic feasibility and clinical safety of an extended sural nerve harvest above the popliteal crease by interfascicular dissection. Methods: An anatomic study using 5 fresh-frozen cadaver legs was conducted, focusing on identifying the anatomic relationship of the sural nerve above the popliteal crease to its surrounding structures and nerve histopathology. A retrospective review was performed of all patients who underwent an extended sural nerve harvest, and patient outcomes, including nerve graft length and postoperative complications, were reviewed to evaluate the clinical feasibility of the extended harvest technique. Results: Anatomic dissection revealed that interfascicular dissection allowed for an additional 14.3 ± 6 cm of nerve length, achieving a total graft length of 49.1 ± 5 cm. Histologic analysis showed no significant differences in fascicle number or axon count along the nerve. A retrospective review, which included 7 adults and 2 pediatric patients, demonstrated that an extended sural nerve harvest was feasible and safe. The maximum graft length was 55 cm, and no intraoperative complications or functional deficits were reported. Conclusion: The extended sural nerve harvest above the popliteal crease with a step-incision approach was both anatomically feasible and clinically safe, providing additional graft length without increasing donor-site morbidity.
Anti-Neoplastic Activity of Estrogen Receptor Beta in Chemoresistant Triple-Negative Breast Cancer
Wang, Xiyin , Emch, Michael J. , Hawse, John R. , Hawse, John R , Goetz, Matthew P.

Mayo Clinic

Cancers | June 25, 2025 | Volume: 17 | Issue: 13 | Pages: 2132

10.3390/cancers17132132 | PMID 40647431 Get It

Background: Targeted therapies, such as endocrine agents, have significantly improved outcomes for patients with estrogen receptor alpha-positive (ERα+) breast cancer. Unfortunately, for patients with triple-negative breast cancer (TNBC), which lack expression of ERα and HER2, there remains a dearth of targeted adjuvant agents. We discovered that estrogen receptor beta (ERβ) is expressed in approximately 20% of TNBC cases, and its activation has been shown to inhibit proliferation, invasion, and migration in preclinical models. However, it remains unclear whether ERβ-targeted therapies maintain efficacy following the development of chemoresistance. Methods: To address this question, we generated ERβ+ TNBC cell line models with acquired resistance to paclitaxel or doxorubicin. We then assessed their response to ERβ-targeted therapies and analyzed transcriptomic changes associated with chemoresistance and ERβ ligand treatment. Results: Chemotherapy-resistant ERβ+ TNBC cells retained sensitivity to ERβ-targeted therapies and, in some cases, exhibited enhanced responsiveness. ERβ expression did not compromise chemotherapy efficacy in treatment-naïve cells. Chemotherapy-resistant cells had a vastly altered transcriptome and surprisingly, a heavily reduced ERβ transcriptome, compared to sensitive cells despite the maintenance of ERβ-driven anti-neoplastic activity. Conclusions: These findings suggest that ERβ remains a relevant drug target in chemotherapy-refractory disease and has aided in the refinement of a minimal ERβ transcriptomic signature associated with response to ERβ-targeting agents, further informing the primary mechanisms through which ERβ elicits its tumor suppressive effects.